Special Issue

Advances in HDAC Inhibitors

Message from the Guest Editors

It has been more than 32 years since the first histone deacetylase inhibitor, the natural product trichostatin A, was described. Despite the advances in drug design that allow selectively targeting the distinct isoforms, only a few drugs have been approved by regulatory agencies worldwide. In humans, histone deacetylase (HDAC) enzymes are comprised of 18 enzymes divided into two mains families: zinc-dependent metalloenzymes (HDAC1-11) and those dependent on NAD+ as a cofactor, known as sirtuins (1-7). Currently, medicinal chemistry approaches aiming to identify synthetic and natural-based HDAC inhibitors have been described in the literature. Although commonly focused on cancer. other indications such as epilepsy, diabetes, pain, neurodegenerative disorders, infectious diseases, rare diseases (e.g., sickle cell disease, Duchenne and Becker muscular dystrophy), etc., have gained attention not only for monotherapy but also for combined therapy. In this Special Issue, we will highlight the recent advances and progress made in the development of HDAC inhibitors from the perspective of medicinal chemistry. Clinical studies describing the advances in HDAC inhibitors are also welcome.

Guest Editors

Prof. Dr. Chung Man Chin

- 1. School of Pharmaceutical Science, State University of São Paulo (UNESP), São Paulo, Brazil
- 2. School of Medicine, Union of the Colleges of the Great Lakes (UNILAGO), SJRP, São Paulo, Brazil

Dr. Jean Leandro Dos Santos

School of Pharmaceutical Sciences, São Paulo State University (UNESP), Araraquara 14800-903, Brazil

Deadline for manuscript submissions

closed (30 September 2023)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/132498

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

